The stock is still down more than 50% year-to-date, although the boost helped it move in the right direction. Research TYME stock prices, stock quotes, stock trends and. The stock had closed at around $1.22 per share by day’s end on Wednesday, which is the price it opened at today–the stock market was not open yesterday in observation of Independence Day. Get todays stock prices, news and investor discussion about Tyme Technologies Inc. ![]() TYME stock is soaring about 22.5% on Friday afternoon following the news, which brought the price of the stock up to $1.50 per share. When is Tyme Technologies's earnings date Tyme Technologies has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 14th, 2022 based off last year's report dates. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. “We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients,” he added. As of 2022 September 09, Friday current price of TYME stock is 0.250 and our data indicates that the asset price has been in a downtrend for the past 1 year (. A high-level overview of Tyme Technologies, Inc. Tyme Technologies said before the open that data from the study of SM-88 as an oral monotherapy revealed that the median overall survival of patients was 6.4 months, which compares favorably next to historical trials that showed survival of 2.0 to 2.5 months. “We believe that these outcomes further justify advancing the development of SM-88,” said Chief Medical Officer Giuseppe Del Priore. Stable Share Price: TYME is more volatile than 75 of US stocks over the past 3 months, typically moving +/- 12 a week. Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology. This led to trading volume increasing to more than 4.1 million shares, which is more than six times the full-day average. ![]() biotechnology company revealed that it had amassed positive updated data regarding its phase 2 study of SM-88, which is a treatment designed to help out patients with pancreatic cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |